INTERPERITONEAL THERAPY WITH CISPLATIN/CARBOPLATIN AND FUDR IN OVARIAN CANCER

顺铂/卡铂和 FUDR 腹膜内治疗卵巢癌

• 批准号: 6115797
• 负责人: FRANCO MUGGIA
• 金额: $ 2.1万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6115797
• 关键词: carboplatin; cis platinum compound; clinical research; combination chemotherapy; female; floxuridine; human subject; human therapy evaluation; injection /infusion; neoplasm /cancer chemotherapy; ovary neoplasms; peritoneal cavity

Standard treatment of stage-III and -IV ovarian cancer has been surgical resection followed by intravenous paclitaxel and a platinum compound, which stops progression in 80% and results in negative findings in 20% of patients at Rsecond-lookS surgery. When residual disease is detected, therapy is less clear. In pilot studies, intraperitoneal (IP) floxuridine (FUdR) and cisplatin showed encouraging results. Subjects to be entered will be those who have completed stage-I chemotherapy for ovarian cancer but at Rsecond-lookS surgery have 2 1 cm peritoneal disease. IP catheters will be placed. FUdR (3g) will be given IP for 3 days, and cisplatin (60 mg/m2) will be given IP on the third day. (When applicable, carboplatin [500 ml] may follow immediately after FudR.). This treatment cycle will be repeated every 3 weeks. Total duration of treatment will consist of 6 consecutive cycles as long as there is no progression or intolerable toxicity. Subjects will be assessed with a CT scan of the abdomen with IP contrast 6 weeks and one year after therapy or whenever recurrence is suspected.

III期和IV期卵巢癌的标准治疗是手术切除，然后静脉注射紫杉醇和铂类化合物，80%的患者停止进展，20%的患者在第二次手术中出现阴性结果。 当检测到残留疾病时，治疗不太清楚。 在初步研究中，腹膜内（IP）尿苷（FUdR）和顺铂显示出令人鼓舞的结果。 入选的受试者将是那些已经完成卵巢癌I期化疗但在第二次手术时有2 - 1cm腹膜疾病的受试者。 将置入IP导管。 FUdR（3g）将IP给药3天，顺铂（60 mg/m2）将在第3天IP给药。(When适用时，FudR后可立即使用卡铂[500 ml]。）该治疗周期将每3周重复一次。 只要没有进展或不可耐受的毒性，治疗的总持续时间将包括6个连续周期。治疗后6周和1年或怀疑复发时，将使用IP造影剂对受试者进行腹部CT扫描评估。